← All trials
NCT05812586
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2023
- Primary completion
- Jun 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Apr 13, 2023
- Last posted
- Apr 13, 2023
- Enrollment
- 760
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- D'Or Institute for Research and EducationLead sponsor
- University of OxfordStudy chair
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.